National Lung Matrix Trial (NLM)
At a Glance
- Status: Active Consortium
- Year Launched: 2014
- Initiating Organization: Cancer Research UK
- Initiator Type: Government
- Disease focus:
- Location: Europe
The National Lung Matrix Trial is the world’s largest precision medicine trial in non-small cell lung cancer and is pivotal in developing novel therapies for patients with this devastating disease. It is a clinician-led collaborative study among the University of Birmingham, Cancer Research UK, Astra Zeneca, and Pfizer. The trial is sponsored by the University of Birmingham and coordinated by the Cancer Research UK Clinical Trials Unit (CRCTU), with Gary Middleton leading as chief investigator.
The National Lung Matrix trial consists of a series of parallel, multi-center, single-arm Phase II trials, each arm testing an experimental targeted drug in a population stratified by multiple prespecified target biomarkers. There are currently 8 targeted drugs and 21 drug-biomarker combinations. The aim is to determine whether there is sufficient signal of activity in any drug-biomarker combination to warrant further investigation. The trial uses a Bayesian adaptive design that gives a more realistic approach to decision-making and flexibility to make conclusions without fixing the exact sample size.
January 2015: Trial announced and launch meeting held in Birmingham
Cancer Research UK, AstraZeneca, and Pfizer jointly fund the program, with support from the National Health Service. In total, this represents about £25 million worth of research.
Sponsors & Partners
Cancer Research UK
University of Birmingham